• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation.

作者信息

Nguyen Andrew T, Berry Gerald J, Witteles Ronald M, Le Dung T, Wu Sean M, Fisher George A, Zhu Han

机构信息

Department of Medicine, Stanford University, Stanford, California, USA.

Department of Pathology, Stanford University, Stanford, California, USA.

出版信息

JACC CardioOncol. 2022 Dec 20;4(5):727-730. doi: 10.1016/j.jaccao.2022.04.007. eCollection 2022 Dec.

DOI:10.1016/j.jaccao.2022.04.007
PMID:36636432
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9830192/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bb/9830192/b18b9c465b64/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bb/9830192/24e72309379d/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bb/9830192/cdb81816a3e6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bb/9830192/b18b9c465b64/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bb/9830192/24e72309379d/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bb/9830192/cdb81816a3e6/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2bb/9830192/b18b9c465b64/gr2.jpg

相似文献

1
Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation.在启动检查点抑制剂两年后发生的迟发性免疫疗法诱导的心肌炎。
JACC CardioOncol. 2022 Dec 20;4(5):727-730. doi: 10.1016/j.jaccao.2022.04.007. eCollection 2022 Dec.
2
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.免疫相关不良事件与免疫检查点抑制剂在有食品和药物管理局批准的免疫治疗适应证的胃肠道癌患者中的疗效。
Oncologist. 2020 Aug;25(8):669-679. doi: 10.1634/theoncologist.2019-0637. Epub 2020 Jan 14.
3
Association between immune-related adverse event timing and treatment outcomes.免疫相关不良事件发生时间与治疗结局的相关性。
Oncoimmunology. 2022 Jan 5;11(1):2017162. doi: 10.1080/2162402X.2021.2017162. eCollection 2022.
4
Immune Checkpoint Inhibitor-Associated Myocarditis: A Run of Bad Luck or Rather Deficient-Monitoring Protocol?免疫检查点抑制剂相关心肌炎：运气不佳还是监测方案存在缺陷？
JACC Case Rep. 2020 Apr 15;2(4):630-635. doi: 10.1016/j.jaccas.2019.12.047. eCollection 2020 Apr.
5
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.免疫检查点抑制剂治疗后的甲状腺免疫相关不良事件。
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3704-e3713. doi: 10.1210/clinem/dgab263.
6
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.癌症患者因出现 ≥2 级免疫相关不良反应而停止使用免疫检查点抑制剂后再次使用的安全性。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-001622.
7
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?免疫检查点抑制剂诱导性心肌炎的诊断标准及筛查证据有哪些？
JACC CardioOncol. 2022 Dec 20;4(5):624-628. doi: 10.1016/j.jaccao.2022.06.008. eCollection 2022 Dec.
8
[Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].[泌尿系统癌症患者免疫检查点抑制剂相关肌炎的临床特征]
Beijing Da Xue Xue Bao Yi Xue Ban. 2022 Aug 18;54(4):644-651. doi: 10.19723/j.issn.1671-167X.2022.04.010.
9
Dynamic gut microbiota changes in patients with advanced malignancies experiencing secondary resistance to immune checkpoint inhibitors and immune-related adverse events.晚期恶性肿瘤患者在对免疫检查点抑制剂产生继发性耐药和发生免疫相关不良事件时肠道微生物群的动态变化。
Front Oncol. 2023 Apr 11;13:1144534. doi: 10.3389/fonc.2023.1144534. eCollection 2023.
10
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素：法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.

引用本文的文献

1
Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence.免疫疗法诱发的心脏毒性：真实世界病例报告、最新信息及临床证据的叙述性综述
Cardiovasc Toxicol. 2025 Jul 13. doi: 10.1007/s12012-025-10038-y.
2
An antibody targeting an immune checkpoint molecule BTN2A2 enhances anti-tumor immunity.一种靶向免疫检查点分子BTN2A2的抗体可增强抗肿瘤免疫力。
Neoplasia. 2025 Jul;65:101161. doi: 10.1016/j.neo.2025.101161. Epub 2025 Apr 21.
3
Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.

本文引用的文献

1
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗癌症期间使用高敏肌钙蛋白I进行心肌炎监测
JACC CardioOncol. 2021 Mar;3(1):137-139. doi: 10.1016/j.jaccao.2021.01.004. Epub 2021 Mar 16.
2
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.癌症患者接受免疫检查点抑制剂治疗后的晚期心脏不良事件。
J Immunother Cancer. 2020 Jan;8(1). doi: 10.1136/jitc-2019-000261.
3
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
免疫检查点抑制剂治疗后的迟发性免疫相关不良事件
JAMA Netw Open. 2025 Mar 3;8(3):e252668. doi: 10.1001/jamanetworkopen.2025.2668.
4
Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review.免疫检查点抑制剂治疗后迟发性心肌炎：病例系列及文献综述
Medicina (Kaunas). 2025 Feb 9;61(2):302. doi: 10.3390/medicina61020302.
5
Toxicity in the era of immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗时代的毒性。
Front Immunol. 2024 Aug 23;15:1447021. doi: 10.3389/fimmu.2024.1447021. eCollection 2024.
6
Stage 4 Non-small Cell Lung Cancer With Human Epidermal Growth Factor Receptor 2 Alterations and Myocarditis Induced by Immune Checkpoint Inhibitors: A Case Report.伴人表皮生长因子受体2改变的IV期非小细胞肺癌及免疫检查点抑制剂诱发的心肌炎：一例报告
Cureus. 2023 Nov 15;15(11):e48859. doi: 10.7759/cureus.48859. eCollection 2023 Nov.
7
Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy.结直肠癌药物治疗相关心血管毒性的最新观点
Pharmaceuticals (Basel). 2023 Oct 11;16(10):1441. doi: 10.3390/ph16101441.
8
Usefulness of Longitudinal Strain to Assess Cancer Therapy-Related Cardiac Dysfunction and Immune Checkpoint Inhibitor-Induced Myocarditis.纵向应变在评估癌症治疗相关心脏功能障碍和免疫检查点抑制剂诱导的心肌炎中的应用价值。
Pharmaceuticals (Basel). 2023 Sep 14;16(9):1297. doi: 10.3390/ph16091297.
9
Immune checkpoint inhibitor-related myocarditis: current understanding and potential diagnostic and therapeutic strategies.免疫检查点抑制剂相关心肌炎：当前认识和潜在的诊断及治疗策略。
Expert Opin Drug Saf. 2023 Jul-Dec;22(10):909-919. doi: 10.1080/14740338.2023.2254218. Epub 2023 Sep 4.
10
A Systematic Review of Myocarditis Induced by Immune Checkpoint Inhibitors: How Concerning Is the Most Common Cardiotoxicity of Immune Checkpoint Inhibitors?免疫检查点抑制剂诱发心肌炎的系统评价：免疫检查点抑制剂最常见的心脏毒性有多令人担忧？
Cureus. 2023 Jul 18;15(7):e42071. doi: 10.7759/cureus.42071. eCollection 2023 Jul.
免疫检查点抑制剂治疗 MSI-H/MMR-D 结直肠癌及耐药机制的研究进展。
Br J Cancer. 2019 Nov;121(10):809-818. doi: 10.1038/s41416-019-0599-y. Epub 2019 Oct 14.
4
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance.免疫治疗停药后的延迟免疫相关事件（DIRE）：远处自身免疫的诊断危害。
J Immunother Cancer. 2019 Jul 3;7(1):165. doi: 10.1186/s40425-019-0645-6.
5
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
6
Reporting of immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关心肌炎的报告。
Lancet. 2018 Aug 4;392(10145):382-383. doi: 10.1016/S0140-6736(18)31542-3.
7
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
8
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关致死性心肌炎报告增加。
Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.
9
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.暴发性心肌炎合并免疫检查点阻断治疗
N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.